Nextech Invest believes that the scientific quality, world class management and investor syndicate are imperative for a winning company. We select investee companies accordingly.
Unmet expertise in scientific and clinical development, and outstanding leadership, combined with a novel and high quality scientific approach is the foundation for the success of a company.
We invest with strong investor syndicates to support the company through different developmental stages with the aim to reach a timely exit, preferably via trade sale - the route independent from financial market conditions.
Emerging cancer treatments are continuously improving efficacy and side effects for the benefit of patients. Antibody therapies and targeted inhibitors selectively kill cancer cells while sparing healthy cells. Immunotherapies can train the patients' own failing immune system to attack/conquer cancer cells.
Your eMail have been successfully registered.Close